Effects of Energy Drinks on Cardiovascular Endpoints

PHASE4RecruitingINTERVENTIONAL
Enrollment

3

Participants

Timeline

Start Date

October 31, 2025

Primary Completion Date

March 31, 2026

Study Completion Date

September 30, 2026

Conditions
Healthy VolunteersSafety After Oral Intake
Interventions
DIETARY_SUPPLEMENT

Energy Drink A + Placebo Capsule

1000 mL caffeine- and taurine-containing commercially available beverage (Formula A) consumed with placebo capsule

DRUG

Placebo Drink + Moxifloxacin Capsule

Placebo drink with 400 mg moxifloxacin capsule

DIETARY_SUPPLEMENT

Placebo Drink + Caffeine Capsule

Placebo drink with 320 mg caffeine capsule

OTHER

Placebo Drink + Placebo Capsule

Placebo drink with placebo capsule

DIETARY_SUPPLEMENT

Energy Drink B

568 mL caffeine- and taurine-containing commercially available beverage (Formula B)

DIETARY_SUPPLEMENT

Control Product + Taurine

Control product with 4000 mg taurine powder

DIETARY_SUPPLEMENT

Control Product + Caffeine + Taurine

Control product with 320 mg caffeine + 4000 mg taurine powder

DIETARY_SUPPLEMENT

Lower Dose Energy Drink A

591 mL caffeine- and taurine-containing commercially available beverage (Formula A)

Trial Locations (1)

95211

RECRUITING

University of the Pacific, Stockton

All Listed Sponsors
lead

University of the Pacific

OTHER